SPOTLIGHT -
Alcon, over a 2-day span in late June, filed one new drug application (NDA) with the FDA and received approval for another.
EyeCon 2023: Reducing patients' retinal burden of care
Week in Review - November 26, 2023
Systematic review suggests vitamin D deficiency doubles risk of noninfectious uveitis
Week in Review - November 12, 2023
Kubota Vision announces multiple partnerships around its eyeMO OCT device
Oculis announces first patient first visit in Phase 2b RELIEF Trial of Topical Anti-TNFα licaminlimab in dry eye disease